Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
biotech
boston blog main
boston top stories
ipo
5
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
5
×
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
novartis
startups
vc
asklepios biopharmaceutical
biogen
cancer immunotherapy
crispr
crispr therapeutics
deals
gene therapy
What
new
5
×
bio
ipo
roundup
life
medicines
million
science
therapeutics
activity
aiming
allogene
ambys
approvals
bails
big
biogen
biotech
biotechs
brand
bridgebio
cancer
capital
car
clamped
club
companies
continued
control
covid
crispr
crop
deadly
deal
debuted
delays
develop
developing
diseases
diversity
Language
unset
Current search:
ipo
×
new
×
photo
×
" san diego blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M